Definium Therapeutics, Inc. (DFTX) Stock Price & Analysis
Definium Therapeutics, Inc. (DFTX) rose 0.56% to USD 43.17 as of July 25, 2026 at 15:03 UTC, according to Nexqual real-time market data.
DFTX last closed at USD 42.93; the session ranged USD 42.69–44.31 on volume of 1,080,727 shares. Market capitalization is $5.73B, with a 52-week range of USD 7.96–49.2 (NMS). Source: Nexqual, July 25, 2026 at 15:03 UTC.
Key Statistics (as of July 25, 2026 at 15:03 UTC)
| Price | USD 43.17 |
|---|---|
| Change | ▲ 0.56% (up) |
| Previous Close | USD 42.93 |
| Open | USD 43.91 |
| Day Range | USD 42.69 – 44.31 |
| 52-Week Range | USD 7.96 – 49.2 |
| Volume | 1,080,727 shares |
| Market Cap | $5.73B |
| Exchange | NMS |
Technical Analysis (DFTX)
Nexqual's technical model rates DFTX "BUY" based on 4 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 15:03 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 59.07 (neutral) |
| vs SMA50 | Above (USD 33.11) |
| MACD | 2.8 (positive) |
Analyst Ratings (DFTX)
Wall Street analysts rate DFTX "Strong Buy" based on 15 analysts, with a mean price target of USD 59.47 (range USD 50–74), per Nexqual as of July 25, 2026 at 15:03 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 59.47 |
| High Target | USD 74 |
| Low Target | USD 50 |
| Buy / Hold / Sell | 15 / 0 / 0 |
Earnings (DFTX)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD -0.55 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.71 vs est -0.49 ▼ miss |
| 2025-12-31 | USD -0.5 vs est -0.49 ▼ miss |
| 2025-09-30 | USD -0.78 vs est -0.5 ▼ miss |
| 2025-06-30 | USD -0.5 vs est -0.36 ▼ miss |
Source: Nexqual, July 25, 2026 at 15:03 UTC.
Financials & Fundamentals (DFTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -94.70% |
| Debt / Equity | 14.62 |
| Current Ratio | 4.69 |
| Total Cash | $373.42M |
| Total Debt | $40.77M |
| Free Cash Flow | $-45.63M |
Source: Nexqual, July 25, 2026 at 15:03 UTC.
Financial Health Score (DFTX)
Nexqual rates Definium Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 15:03 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $373M cash vs $41M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$145M |
| Efficiency | Critical — ROE -95%, ROA -35.7% |
Ownership (DFTX)
| Insider Ownership | +1.33% |
|---|---|
| Institutional Ownership | +73.92% |
| Shares Outstanding | 132.74M |
| Float | 107.08M |
| Short % of Float | +8.07% |
Source: Nexqual, July 25, 2026 at 15:03 UTC.
Leadership (DFTX)
Definium Therapeutics, Inc. is led by Robert Barrow (age 36), CEO & Director, per Nexqual as of July 25, 2026 at 15:03 UTC.
| CEO & Director | Robert Barrow (age 36) |
|---|---|
| Chief Financial Officer | Brandi L. Roberts (age 51) |
| Senior Vice President of Pharmaceutical Development & Operations | Peter Mack |
| Vice President of Corporate Communications | Beth Calitri |
Major Backers & Investors (DFTX)
Notable institutional backers of Definium Therapeutics, Inc. include Driehaus Capital Management, LLC, Avoro Capital Advisors LLC, Janus Henderson Group PLC, according to Nexqual as of July 25, 2026 at 15:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Driehaus Capital Management, LLC | 5.42% |
| Avoro Capital Advisors LLC | 4.58% |
| Janus Henderson Group PLC | 3.26% |
| Deep Track Capital, Lp | 2.75% |
| Octagon Capital Advisors LP | 2.24% |
| Fidelity | 2.11% |
| Commodore Capital Lp | 1.83% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.13% |
| Geode Capital | 2.29% |
| State Street | 2.27% |
Source: Nexqual, July 25, 2026 at 15:03 UTC.
From Definium Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Our patent portfolio, as of February 19, 2026, contains 12 issued U.S. patents, 29 pending U.S. applications, and 1 pending patent cooperation treaty application that are either solely owned by us or in-licensed, as well as certain foreign counterparts of a subset of these patent applications in foreign countries, including Australia, Brazil, Canada, China, Europe, Hong Kong, India, Israel, Japan, Singapore, South Korea, and Taiwan.
- Intra-Cellular Therapies, now a part of J&J ("Intra-Cellular"), is currently developing multiple product candidates that are in various phases of development for the treatment of GAD and MDD, including CAPLYTA (lumateperone), which was approved by the FDA in November 2025 as an adjunctive treatment for adults with MDD, and ITI-1284 ODT-SL for GAD.
- IND Application An IND is a request for authorization from the FDA to administer an investigational drug product to humans.
- Our second lead product candidate, DT402 (previously referred to as MM402), also referred to as R(-)-MDMA, is our proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine ("MDMA"), which we are developing for the treatment of adults with autism spectrum disorder ("ASD").
Partnerships
- Catalent In August 2023, we announced an exclusive licensing agreement with Catalent for its patented Zydis® ODT technology.
- Research Collaborations On April 1, 2020, we entered into a multi-year, exclusive collaboration with Dr.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CMPS | COMPASS Pathways Plc - American | USD 11.26 | ▼ 5.62% |
| HELP | Cybin Inc. | USD 7.62 | ▼ 2.56% |
| AACG | ATA Creativity Global | USD 0.89 | ▼ 2.52% |
| CLOV | Clover Health Investments, Corp | USD 4.32 | ▼ 7.49% |
| MVIS | Microvision, Inc. | USD 0.25 | ▼ 16.1% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 15:03 UTC. This page is informational and not investment advice.